Non-operative Management (NOM) of Rectal Cancer: Literature Review and Translation of Evidence into Practice

1.

Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.

CAS  PubMed  Google Scholar 

2.••

Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:501–13 Meta-analysis comparing oncologic outcomes for NOM vs. patients who either had a cCR before surgery or pCR at time of surgery, with findings including no differences in non-regrowth recurrences or cancer-specific mortality between groups.

PubMed  Google Scholar 

3.

Ruppert R, Kube R, Strassburg J, et al. Avoidance of overtreatment of rectal cancer by selective chemoradiotherapy: results of the optimized surgery and MRI-based multimodal therapy trial. J Am Coll Surg. 2020. https://doi.org/10.1016/j.jamcollsurg.2020.06.023.

4.

Battersby NJ, How P, Moran B, Stelzner S, West NP, Branagan G, et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg. 2016;263:751–60.

PubMed  Google Scholar 

5.

Wrenn SM, Cepeda-Benito A, Ramos-Valadez DI, Cataldo PA. Patient perceptions and quality of life after colon and rectal surgery: what do patients really want? Dis Colon Rectum. 2018;61:971–8.

PubMed  Google Scholar 

6.

Couwenberg AM, Intven MPW, Burbach JPM, Emaus MJ, van Grevenstein WMU, Verkooijen HM. Utility scores and preferences for surgical and organ-sparing approaches for treatment of intermediate and high-risk rectal cancer. Dis Colon Rectum. 2018;61:911–9.

PubMed  Google Scholar 

7.

2017 European Society of Coloproctology (ESCP) collaborating group. Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral of surgery. Color Dis. 2018;20(Suppl 6):58–68.

Google Scholar 

8.

Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Silva e Sousa AH, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711–7 discussion 717-718.

PubMed  PubMed Central  Google Scholar 

9.

Crawford A, Firtell J, Caycedo-Marulanda A. How is rectal cancer managed: a survey exploring current practice patterns in Canada. J Gastrointest Cancer. 2019;50:260–8.

CAS  PubMed  Google Scholar 

10.

National Comprehensive Care Network. Rectal Carcinoma (Version 6.2020). https://www.nccn.org/professionals/physician_gls/pdf/rectal_blocks.pdf. All right reserved Accessed September 7, 2020.

11.

Yahya J, Herzig D, Farrell M, Degnin C, Chen Y, Holland J, et al. Survey results of US radiation oncology providers’ contextual engagement of watch-and-wait beliefs after a complete clinical response to chemoradiation in patients with local rectal cancer. J Gastrointest Oncol. 2018;9:1127–32.

PubMed  PubMed Central  Google Scholar 

12.

Kennedy ED, Borowiec AM, Schmocker S, Cho C, Brierley J, Li S, et al. Patient and physician preferences for nonoperative management for low rectal cancer: is it a reasonable treatment option? Dis Colon Rectum. 2018;61:1281–9.

PubMed  Google Scholar 

13.••

Dattani M, Heald RJ, Goussous G, Broadhurst J, Sao Juliao GP, Habr-Gama A, et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg. 2018;268:955–67 Meta-analysis noting frequency of cCR and the timing and frequency of the various patterns-of-failure including rectal tumor regrowth, nonregrowth pelvic recurrences, and distant metastases. An 82% R0 surgical salvage rate was noted.

PubMed  Google Scholar 

14.

Fiorica F, Trovo M, Anania G, Marcello D, Di Benedetto F, Marzola M, et al. Is it possible a conservative approach after radiochemotherapy in locally advanced rectal Cancer (LARC)? A systematic review of the literature and meta-analysis. J Gastrointest Cancer. 2019;50:98–108.

CAS  PubMed  Google Scholar 

15.

Huh JW, Maeda K, Liu Z, Wang X, Roslani AC, Lee WY. Current status of “watch-and-wait” rectal cancer treatment in Asia-Pacific countries. Ann Coloproctol. 2020;36:70–7.

PubMed  PubMed Central  Google Scholar 

16.

Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev. 2021;26:1–39.

17.••

Chadi SA, Malcomson L, Ensor J, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:825–36 Individual patient data meta-analysis showing that among 20 core variables across 11 data sets, a higher T-stage was the only factor associated with a risk of increased rectal tumor regrowth.

18.

Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5:e185896.

PubMed  PubMed Central  Google Scholar 

19.

van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537–45.

PubMed  Google Scholar 

20.

Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17:174–83.

PubMed  Google Scholar 

21.

Habr-Gama A, Sabbaga J, Gama-Rodrigues J, São Julião GP, Proscurshim I, Bailão Aguilar P, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum. 2013;56:1109–17.

PubMed  Google Scholar 

22.

Habr-Gama A, Gama-Rodrigues J, São Julião GP, Proscurshim I, Sabbagh C, Lynn PB, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88:822–8.

PubMed  Google Scholar 

23.

Martens MH, Maas M, Heijnen LA, Lambregts DMJ, Leijtens JWA, Stassen LPS, et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst. 2016;108:djw171. https://doi.org/10.1093/jnci/djw171.

Article  PubMed  Google Scholar 

24.

van der Sande ME, Figueiredo N, Beets GL. Management and outcome of local regrowths in a watch-and-wait prospective cohort for complete responses in rectal cancer. Ann Surg. 2020. https://doi.org/10.1097/SLA.0000000000003738.

25.

Roxburgh CSD, Strombom P, Lynn P, Gonen M, Paty PB, Guillem JG, et al. Role of the interval from completion of neoadjuvant therapy to surgery in postoperative morbidity in patients with locally advanced rectal cancer. Ann Surg Oncol. 2019;26:2019–27.

PubMed  PubMed Central  Google Scholar 

26.•

Couwenberg AM, JPM B, Berbee M, et al. Efficacy of dose-escalated chemoradiation on complete tumor response in patients with locally advanced rectal cancer (RECTAL-BOOST): a phase 2 randomized controlled trial. Int J Radiat Oncol Biol Phys. 2020. https://doi.org/10.1016/j.ijrobp.2020.06.013Phase II trial RCT that did not find improvement in the rate of pCR or sustained cCR through dose escalation, with the experimental arm receiving a further 5 × 3 Gy boost following the standard arm’s 25 × 2 Gy with concurrent capecitabine.

27.

Sao Juliao GP, Habr-Gama A, Vailati BB, et al. Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer? Eur J Surg Oncol. 2018;44:93–9.

PubMed  Google Scholar 

28.

Habr-Gama A, Sao Juliao GP, Vailati BB, Sabbaga J, Aguilar PB, Fernandez LM, et al. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: the impact of radiation therapy dose-escalation and consolidation chemotherapy. Ann Surg. 2019;269:102–7.

PubMed  Google Scholar 

29.

Socha J, Pietrzak L, Zawadzka A, Paciorkiewicz A, Krupa A, Bujko K. A systematic review and meta-analysis of pT2 rectal cancer spread and recurrence pattern: implications for target design in radiation therapy for organ preservation. Radiother Oncol. 2019;133:20–7.

PubMed  Google Scholar 

30.

van der Sande ME, Hupkens BJP, Berbee M, van Kuijk SMJ, Maas M, Melenhorst J, et al. Impact of radiotherapy on anorectal function in patients with rectal cancer following a watch and wait programme. Radiother Oncol. 2019;132:79–84.

PubMed  Google Scholar 

31.

Rombouts AJM, Hugen N, Verhoeven RHA, Elferink MAG, Poortmans PMP, Nagtegaal ID, et al. Tumor response after long interval comparing 5x5Gy radiation therapy with chemoradiation therapy in rectal cancer patients. Eur J Surg Oncol. 2018;44:1018–24.

CAS  PubMed  Google Scholar 

32.

Lorenzon L, Evrard S, Beets G, Gonzalez-Moreno S, Kovacs T, D’Ugo D, et al. Global variation in the long-term outcomes of ypT0 rectal cancers. Eur J Surg Oncol. 2020;46:420–8.

PubMed  Google Scholar 

33.

Smart CJ, Korsgen S, Hill J, Speake D, Levy B, Steward M, et al. Multicentre study of short-course radiotherapy and transanal endoscopic microsurgery for early rectal cancer. Br J Surg. 2016;103:1069–75.

CAS  PubMed  Google Scholar 

34.

Jones HJS, Al-Najami I, Cunningham C. Quality of life after rectal-preserving treatment of rectal cancer. Eur J Surg Oncol. 2020;46:2050–6. https://doi.org/10.1016/j.ejso.2020.07.018.

Article  PubMed  Google Scholar 

35.

Latkauskas T, Pauzas H, Kairevice L, Petrauskas A, Saladzinskas Z, Janciauskiene R, et al. Preoperative conventional chemoradiotherapy versus short-course radiotherapy with delayed surgery for rectal cancer: results of a randomized controlled trial. BMC Cancer. 2016;16:927.

PubMed  PubMed Central  Google Scholar 

36.

Ciseł B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30:1298–303.

PubMed  Google Scholar 

37.

van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EMK, et al. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - results of the international randomized RAPIDO-trial. Radiother Oncol. 2020;147:75–83.

PubMed  Google Scholar 

38.

Appelt AL, Ploen J, Harling H, Jensen FS, Jensen LH, Jorgensen JCR, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919–27.

PubMed  Google Scholar 

39.

Dizdarevic E, Frostrup Hansen T, Ploen J, Henrik Jensen L, Lindebjerg J, Rafaelsen S, et al. Long-term patient-reported outcomes after high-dose chemoradiation therapy for nonsurgical management of distal rectal cancer. Int J Radiat Oncol Biol Phys. 2020;106:556–63.

CAS  PubMed  Google Scholar 

40.

Gerard J-P, Barbet N, Gal J, et al. Planned organ preservation for early T2-3 rectal adenocarcinoma: a French, multicentre study. Eur J Cancer. 2019;108:1–16.

PubMed  Google Scholar 

41.

Sun Myint A, Smith FM, Gollins SW, et al. Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation? Br J Radiol. 2017;90:20170175.

PubMed  PubMed Central  Google Scholar 

42.

Breugom AJ, Swets M, Bosset J-F, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200–7.

CAS  PubMed  Google Scholar 

43.

Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4:e180071.

PubMed  PubMed Central 

留言 (0)

沒有登入
gif